The Kovid-1V vaccine works for 12- to 15-year-olds, Pfizer said

Pfizer’s coronavirus vaccine works very well in children aged 12 to 15, the pharmaceutical giant reported Wednesday.

Pfizer said in a press release that while more than 2,200 adolescents in the United States were in the final stages of their studies, not a single vaccinated person was infected with Covid-1. The results suggest that the Pfizer-Biotech vaccine may be more effective in adults aged 12 to 15 years than in adults.

Pfizer has not yet released trial data. The company plans to submit the results to the FDA next week, said CEO Albert Borla, “hoping to start vaccinating this age before the start of the next school year.”

If it receives urgent approval, Pfizer’s vaccine will be the first in the United States for children under the age of 16. Kovid-1 that the virus can no longer spread effectively. President Joe Biden has called for the vaccination of high school-age students and primary school students in early 2022 through the fall in the United States, if the results of tests announced by Pfizer show that the vaccine is really safe and effective among them.

Pfizer said the experiment showed that the vaccine was safe in 12- to 15-year-olds, whose side effects “are consistent with observations in participants aged 16 to 25 years.”

The Pfizer vaccine was first approved for emergency use in December for people aged 16 and over, and more than 755 million doses have been given to Americans since then. A clinical trial in the last episode found that it is 5% effective in reducing covid-1 infections in adults; A recent study found that similar 90% efficacy results “in the real world” since approval.

In the announcement, Pfizer further said that it has started vaccinating children aged 5 to 11 in a related global test and next week it will start vaccinating a group of children aged 2 to 5 years.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button